+ Watch NVIV
on My Watchlist
anything but optomistic
As always, credit is due to anyone who picked InVivo at a share price around 1.1 in the depths of despair in November. The stock had plunged like a collapsing scam, and although the spectre of scam still exists the company hasn't exactly collapsed. Instead, they've been doing what they've said they were going to do ever since the crash in August after long delays in the development process were announced - they've garnered conditional approval for their biopolymer scaffolding trial protocol and begun preparations for patient accrual planned to begin in March. Does any of this justify a 190M market cap for this sketchy, unpredictable outfit with 18M in cash and years of expensive trials ahead? Of course not.
Wow... meant to pick this earlier today before it suddenly popped 55%!!
cured monkeys of spinal damage induced paralysis - next step, humansstock at an all time lowheavy accumulation indicates possible buyout target
The big IF is successfully navigating clinical human trials. If it does so then this has massive upside potential.
Next Top Dog and First Mover in medical device company.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions